This study aimed to fill the gaps by comparing the efficacy and safety of ondansetron versus metoclopramide for the control of gastroesophageal reflux disorder in children 1-12 months of age, presenting at the outdoor department of Allama Iqbal Teaching Hospital, Dera Ghazi Khan.

Since the FDA issued a warning against domperidone as a potential proarrhythmic drug in children, its use has been widely discouraged and no longer recommended in safe practices. This warning at one end persuaded the pediatricians to search for the new options; on the other end, the use of metoclopramide, H2 receptor antagonists, and alginate-based medications became superfluous, opening a wide area of research in search of the next potential best option. The findings of this study would add to the existing statistics and help clinicians to have better outcomes among infants with gastroesophageal reflux disorder.

Inclusion Criteria:

• Infants of any gender
• Aged 1-12 months
• Presenting with symptoms of gastroesophageal reflux disease not responding to dietary modifications and positioning
• Afebrile at the time of presentation
• Vitally stable

Exclusion Criteria:

• No evidence of hypertrophic pyloric stenosis on ultrasonography
• Children with congenital heart disease
• Any history of prior illness associated with symptoms
• With abdominal distension
• Neurological impairment, like developmentally delayed, grossly microcephalic

If a reasonable request is made, data can be shared.